Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Show more
Location: 400 Fifth Avenue, Waltham, MA, 02451, United States | Website: https://www.ardelyx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.301B
52 Wk Range
$3.21 - $7.18
Previous Close
$5.40
Open
$5.44
Volume
3,312,548
Day Range
$5.43 - $5.64
Enterprise Value
1.297B
Cash
238.5M
Avg Qtr Burn
-13.37M
Insider Ownership
2.50%
Institutional Own.
72.20%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tenapanor (Ibsrela) (NHE3 sodium transport inhibitor) Details Irritable bowel syndrome, Constipation | Approved Quarterly sales | |
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease | Approved Quarterly sales | |
RDX013 Details Hyperkalemia | Failed Discontinued |